The purpose of this volume is to highlight wide-ranging applications of genomics in the area of applied mycology and biotechnology.The volume covers: a brief overview on fungal genomics; meiotic recombination in fungi; molecular genetics of circadian rhythms; genome sequencing; transposable elements; mitochondrial genomes; ribosome biogenesis; pathogenicity genes; genetic improvement of yeasts; microarrays: techniques and applications; fungal germplasm and data bases. Although it is difficult to develop a comprehensive volume on fungal genomics because of the range and complexity of the emerging knowledge, an attempt has been made to bring together pertinent information that will serve the needs of the reader, provide a quick reference to material that might otherwise be difficult to locate, and furnish a starting point for further study.
Frontiers in Biochip Technology Dr. Wan-Li Xing and Dr. Jing Cheng Frontiers in Biochip Technology serves as an essential collection of new research in the field of biochip technology. This comprehensive collection covers emerging technologies and cutting –edge research in the field of biochip technology, with all chapters written by the international stars of this evolving field. Key topics and current trends in biochip technology covered include: -microarray technology and its applications - microfluidics - drug discovery - detection technology - lab-on-chip technology and bioinformatics. Frontiers in Biochip Technology is an important volume for all biotechnologists, bioengineers, genetic engineers, pharmacological researchers, and general bench researchers who want to be up-to-date on the latest advances in the rapidly growing field of biochip technology. The Editors: Dr. Wan-Li Xing, Tsinghua University School of Medicine, National Engineering Research Center for Beijing Biochip Technology (NERCBBT), and CapitalBio Corporation, Beijing, China Dr. Xing is a Professor at Medical Systems Biology Research Center, Tsinghua University School of Medicine, and also serves as the Executive Deputy Director at NERCBBT, CapitalBio Corporation, a world-leader in biochip research. Dr. Xing has published widely and obtained many patents and applications. Dr. Jing Cheng, Tsinghua University School of Medicine, National Engineering Research Center for Beijing Biochip Technology (NERCBBT), and CapitalBio Corporation, Beijing, China Dr. Jing Cheng is the Cheung Kong Professor at Medical Systems Biology Research Center, Tsinghua University School of Medicine, the Director of NERCBBT and CEO & CTO of CapitalBio. Dr. Cheng developed the world’s first system of laboratory-on-a-chip in 1998; this work was featured in the front-cover story of the June 1998 issue of Nature Biotechnology and cited as the breakthrough of the year by Science in the same year. He has been awarded Nanogen’s most prestigious award Nano Grant, Distinguished Achievement Award for Overseas Chinese Scholars Returned, China’s Science & Technology Award for Outstanding Youth, and Qiushi Technology Transfer Award for Outstanding Youth. Dr. Cheng has published over 90 peer-reviewed papers. In addition, he has obtained over 60 European and U.S. patents and applications.
This volume provides a comprehensive review of China's healthcare system and policy reforms in the context of the global economy. Following a value-chain framework, the 16 chapters cover the payers, the providers, and the producers (manufacturers) in China's system. It also provides a detailed analysis of the historical development of China's healthcare system, the current state of its broad reforms, and the uneasy balance between China's market-driven approach and governmental regulation. Most importantly, it devotes considerable attention to the major problems confronting China, including chronic illness, public health, and long-term care and economic security for the elderly. Burns and Liu have assembled the latest research from leading health economists and political scientists, as well as senior public health officials and corporate executives, making this book an essential read for industry professionals, policymakers, researchers, and students studying comparative health systems across the world.
In this book the reader will find a collection of chapters written by different research teams describing different aspects of peripheral T-cell lymphoma pathobiology, classification, and treatment. This work is mainly addressed to researchers already working in this area, but it is also accessible to anyone with a scientific background who desires to have an updated overview of the recent progress in this domain. It will also be valuable to scientists and physicians who have become newly involved in this field. Each chapter is self-contained and can be read independently of the others. This book intends to provide highlights of the current research as well as the current gold standards for diagnosis and treatment of these diseases, showing the recent advances in the personalized approach to T-cell derived lymphomas.
Chemical Analysis of Food: Techniques and Applications reviews new technology and challenges in food analysis from multiple perspectives: a review of novel technologies being used in food analysis, an in-depth analysis of several specific approaches, and an examination of the most innovative applications and future trends. This book won a 2012 PROSE Award Honorable Mention in Chemistry and Physics from the Association of American Publishers. The book is structured in two parts: the first describes the role of the latest developments in analytical and bio-analytical techniques and the second reviews the most innovative applications and issues in food analysis. Each chapter is written by experts on the subject and is extensively referenced in order to serve as an effective resource for more detailed information. The techniques discussed range from the non-invasive and non-destructive, such as infrared spectroscopy and ultrasound, to emerging areas such as nanotechnology, biosensors and electronic noses and tongues. Important tools for problem-solving in chemical and biological analysis are discussed in detail. - Winner of a PROSE Award 2012, Book: Honorable Mention in Physical Sciences and Mathematics - Chemistry and Physics from the American Association of Publishers - Provides researchers with a single source for up-to-date information in food analysis - Single go-to reference for emerging techniques and technologies - Over 20 renowned international contributors - Broad coverage of many important techniques makes this reference useful for a range of food scientists
Diabetes mellitus is a disease with tremendous health and economic burden. A better understanding of how normal glucose homeostasis is maintained and the pathogenesis is important to identify new ways for diabetes treatment. This book addresses multiple aspects of this area of research. - Written by experts in the field - Informs on important topics related to the regulation of glucose homeostasis and the pathogenesis of diabetes mellitus, a field of intense research interest
Cyclin Dependent Kinase 5 provides a comprehensive and up-to-date collection of reviews on the discovery, signaling mechanisms and functions of Cdk5, as well as the potential implication of Cdk5 in the treatment of neurodegenerative diseases. Since the identification of this unique member of the Cdk family, Cdk5 has emerged as one of the most important signal transduction mediators in the development, maintenance and fine-tuning of neuronal functions and networking. Further studies have revealed that Cdk5 is also associated with the regulation of neuronal survival during both developmental stages and in neurodegenerative diseases. These observations indicate that precise control of Cdk5 is essential for the regulation of neuronal survival. The pivotal role Cdk5 appears to play in both the regulation of neuronal survival and synaptic functions thus raises the interesting possibility that Cdk5 inhibitors may serve as therapeutic treatment for a number of neurodegenerative diseases.
This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.
Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector. The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver). The book encompasses both large-scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. - Concisely summarizes the therapeutic implications of recent, large-scale epigenome studies, including the cancer epigenome atlas - Discusses targeted isoform specific versus pan-specific inhibitors, a rational drug design approach to epigenetics relevant to pharmacoepigenetic clinical applications - Covers new findings in the interplay between cancer stem cells (CSCs) and drug resistance, demonstrating that epigenetic machinery is a candidate target for the eradication of these CSCs
